IL6R and rheumatoid arthritis: For example, the humanized anti-IL-6R antibody tocilizumab (Actemra, RoActemra in the EU) that has been approved in more than 100 countries for rheumatoid arthritis and other autoinflammatory diseases, is currently examined in combination with gemcitabine/nab-paclitaxel as first-line treatment in patients with locally advanced or metastatic pancreatic cancer (MD 2022).